

## Kazuistiky

- 2 **Vildagliptin a jeho potenciál v léčbě diabetu 2. typu**  
MUDr. Barbora Doležalová Fakulta zdravotnických studií Univerzity Pardubice, IDE CR, s. r. o., Chrudim
- 2 **Ustekinumab v léčbě pacientky s těžkou ložiskovou a artropatickou psoriázou**  
MUDr. Jaroslava Vaněčková Klinika nemocí kožních a pohlavních FN Hradec Králové
- 2 **Pokles hmotnosti a zlepšení metabolického profilu u obézní pacientky s diabetem 2. typu za šest měsíců po zavedení EndoBarrieru**  
MUDr. Zuzana Vlasáková Centrum diabetologie IKEM  
MUDr. Marek Beneš Klinika hepatogastroenterologie IKEM
- 2 **Mirabegron – klinické zkušenosti**  
MUDr. Kamil Švábík, Ph.D. Gynekologicko-porodnická klinika VFN a 1. LF UK
- 3 **Klinicky izolovaný syndrom a léčba glatiramer acetátem**  
doc. MUDr. Radomír Taláb, CSc. Neurologie – RS centrum, s. r. o., Hradec Králové  
MUDr. Marika Talábová Neurologická klinika LF UK a FN Hradec Králové
- 3 **Postavení belimumabu v léčbě pacientky s kombinací myasthenia gravis a systémového lupusu erythematodes**  
MUDr. Zuzana Potyšová Klinika nefrologie VFN a 1. LF UK Praha

# Vildagliptin a jeho potenciál v léčbě diabetu 2. typu

MUDr. Barbora Doležalová

Fakulta zdravotnických studií Univerzity Pardubice, IDE CR, s. r. o., Chrudim

- 1 DeFronzo, R. A.: From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*, 2009, 58, s. 773–795.
- 2 Inzucchi, S. E., et al.: Management of hyperglycemia in type 2 diabetes: A patient-centered approach. *Diabetes Care*, 19. 4. 2012, publikováno online před tiskem.

# Ustekinumab v léčbě pacientky s těžkou ložiskovou a artropatickou psoriázou

MUDr. Jaroslava Vaněčková Klinika nemocí kožních a pohlavních FN Hradec Králové

- 1 Pavelka, K. – Venkovský, J. – Tezová, D.: TNF blokující léky. In: Pavelka, K., et al (eds): *Klinická revmatologie*. Galén, Praha, 2005, s. 147–163.
- 2 Weger, W.: Current status et new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. *Br J Pharmacol*, 2010, 160, s. 810–820.

# Pokles hmotnosti a zlepšení metabolického profilu u obézní pacientky s diabetem 2. typu za šest měsíců po zavedení EndoBarrieru

MUDr. Zuzana Vlasáková Centrum diabetologie IKEM

MUDr. Marek Beneš Klinika hepatogastroenterologie IKEM

- 1 De Moura, E. G. – Martins, B. C. – Polez, G. S., et al.: Metabolic improvements in obese type2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. *Diabetes Technol Ther*, 2012, 14, s. 183–189.
- 2 Rodriguez, L. – Reyes, E. – Fagalde, P., et al.: Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. *Diabetes Technol Ther*, 2009, 11, s. 725–732.
- 3 De Jonge, C. – Rensen, S. S. – Verdam, F. J., et al.: Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. *Obes Surg*, 2013, 23, s. 1354–1360.
- 4 Munoz, R. – Carmody, J. S. – Stylopoulos, N., et al.: Isolated duodenal exclusion increases energy expenditure and improves glucose homeostasis in diet-induced obese rats. *Am J Physiol Integr Comp Physiol*, 2012, 303, s. R985–R993.
- 5 Patriki, A. – Aisa, M. C. – Annetti, C., et al.: How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number. *Surgery*, 2007, 142, s. 74–85.
- 6 Lee, W. J. – Hur, K. Y. – Lakdawala, M., et al.: Gastrointestinal metabolic Sumerly for the treatment of diabetic patients: a multi-institutional international study. *J Gastrointest Surg*, 2012, 16, s. 45–51.
- 7 Lakdawala, M. – Shaikh, S. – Bandukwala, S., et al.: Roux-en-Y gastrin bypass stands the test of time: 5-year results in low body mass index (30–35 kg/m<sup>2</sup>) Indian patients with type 2 diabetes mellitus. *Surg Obes Relat Dis*, 2012, 9, s. 370–378.
- 8 Boza, C. – Muñoz, R. – Salina, J.: Safety and eddicacy od Roux-en-Y gastric bypass to treat type 2 diabetes mellitus in nonseverely obese patients. *Obes Surg*, 2011, 21, s. 1330–1336.
- 9 Li, Q. – Chen, L. – Yang, Z., et al.: Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index < 35 kg/m<sup>2</sup>. *Diabetes Obes Metab*, 2012, 14, s. 262–270.
- 10 Reis, C. E. – Alvarez-Leite, J. I. – Bressan, J. – Alfenas, R. C.: Role of bariatric–metabolic surgery in the treatment of obese type 2 diabetes with body mass index < 35 kg/m<sup>2</sup>: a literature review. *Diabetes Technol Ther*, 2012, 14, s. 365–372.

# Mirabegron – klinické zkušenosti

MUDr. Kamil Švábík, Ph.D. Gynekologicko-porodnická klinika VFN a 1. LF UK

- 1 Abou-Gamrah, A. – Fawzy, M. – Sammour, H. – Tadros, S.: Ultrasound assessment of bladder wall thickness as a screening test for detrusor instability. *Arch Gynecol Obstet*, 2014, 289, s. 1023–1028.
- 2 Abrams, P. L. – Cardozo, M. – Fall, D. – Griffiths, P. – Rosier, U. – Ulmsten, P. – van Kerrebroeck, A. V. – Wein, A.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Am J Obstet Gynecol*, 2002, 187, s. 116–126.
- 3 Bhide, A. A. – Cartwright, R. – Khullar, V. – Digesu, G. A.: Biomarkers in overactive bladder. *Int Urogynecol J*, 2013, 24, s. 1065–1072.
- 4 Chapple, C.R. – Amarengo, G. – Lopez Aramburu, M. A. – Everaert, K. – Liehne, J. – Lucas, M., et al.: A proof-of-concept study: mirabegron, a new therapy for overactive bladder. *NeuroUrol Urodyn*, 2013, 32, s. 1116–1122.
- 5 Milsom, I. – Abrams, P. – Cardozo, L., et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. *Bju International*, 2001, 87, s. 760–766.
- 6 Novara, G. – Cornu, J. N.: Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns. *Eur Urol*, 2013, 63, s. 306–308.
- 7 Sanford, M.: Mirabegron: a review of its use in patients with overactive bladder syndrome. *Drugs*, 2013, 73, s. 1213–1225.
- 8 Wu, T. – Duan, X. – Cao, C. X., et al.: The role of mirabegron in overactive bladder: a systematic review and meta-analysis. *Urol Int*, 2014, 93, s. 326–337.

# Klinicky izolovaný syndrom a léčba glatiramer acetátem

doc. MUDr. Radomír Taláb, CSc. Neurologie – RS centrum, s. r. o., Hradec Králové

MUDr. Marika Talábová Neurologická klinika LF UK a FN Hradec Králové

- 1 Kappos, L. – Freedman, M. S. – Polman, C. H., et al.: BENEFIT Study Group. Long term effect of early treatment with interferon beta-1b after first clinical event suggestive of multiple sclerosis: 5-years active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurol*, 2009, 8, s. 987–997.
- 2 Nixon, R. – Bergvall, N. – Tomic, D. – Sfikas, N. – Cutter, G. – Giovannoni, G.: No evidence of disease activity: Indirect comparisons of oral therapies for treatment of relapsing-remitting multiple sclerosis. *AdvTher*, [www.advancesintherapy.com](http://www.advancesintherapy.com), 21. 11. 2014.
- 3 Polman, C. H. – Reingold, S. C. – Banwell, B. – Clanet, M. – Cohen, J. A., et al.: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol*, 2011, 69, s. 292–302.
- 4 Banwel, B. – Ghezzi, A. – Bar-Or, A., et al.: Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. *Lancet Neurol*, 2007, 6, s. 887–902.
- 5 Wilejto, M. – Shroff, M. – Buncic, J. R., et al.: The clinical features, MR findings, and outcome of optic neuritis in children. *Neurology*, 2006, 67, s. 258–262.
- 6 Tintoré, M. – Rovira, A. – Martínéz, M., et al.: Isolated demyelinating syndromes: comparison of different MR paging criteria to predict conversion to clinically definite multiple sclerosis. *Am J Neuroradiol*, 2000, 21, s. 702–706.
- 7 Jacobs, L. D. – Beck, R. W. – Simon, J. H. – Kinkel, R. P. – Brownschield, C. M. – Murray, T. J., et al.: CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. *N Engl J Med*, 2000, 343, s. 898–904.
- 8 Comi, G. – Filippi, M. – Barkhof, F. – Durelli, L. – Edan, G. – Fernández, O., et al.: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. *Lancet*, 2001, 357, s. 1576–1582.
- 9 Kappos, L. – Polman, C. H. – Freedman, M. S. – Edan, G. – Hartung, H. P. – Miller, D. H., et al.: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*, 2006, 67, s. 1242–1249.
- 10 Cleris, M. – Faggiano, F. – Palace, J. – Rice, G. – Tintoré, M. – Durrelli, L.: Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. *Cochrane database of systematic reviews* (online), 2008, 2, CD005378.
- 11 Banwell, B. L.: Pediatric multiple sclerosis. *Curr Neurol Neurosci Rep*, 2004, 4, s. 245–252.
- 12 Achiron, A. – Kishner, I. – Sarova-Pinhas, I., et al.: Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. *Arch Neurol*, 2004, 61, s. 1515–1520.
- 13 Lehmann, H. C. – Hartung, H. P. – Hetzel, G. R. – Stüve, O. – Kieseir, B. C.: Plasma exchange in neuroimmunological disorders: Part 1: rationale and treatment of inflammatory central nervous system disorders. *Arch Neurol*, 2006, 63, s. 930–935.
- 14 Talab, R.: Glatirameracetat. *Farmakoterapie*, 2006, 3, s. 271–276.
- 15 Farina, C. – Weber, M. S. – Meinl, E. – Wekerle, H. – Hohlfeld, R.: Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. *Lancet Neurol*, 2005, 4, s. 567–575.

# Postavení belimumabu v léčbě pacientky s kombinací myasthenia gravis a systémového lupusu erythematodes

MUDr. Zuzana Potyšová Klinika nefrologie VFN a 1. LF UK Praha

- 1 Kamal, A. – Khamashta, M.: The efficacy of novel B cell biologics as the future of SLE treatment: A review. *Autoimmun Rev*, 2014, 13, s. 1094–1101.
- 2 Cíferská, H.: Belimumab v terapii systémového lupusu erythematodes. *Farmakoterapie*, 2012, 1.